Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
Bioethics of GM Humans
The Journal of the Royal Society of Medicine recently published two opposing viewpoints on the ethics of using gene-editing technology human embryos. One article, written by an actress who has a rare form of dwarfism, maintains that gene editing does not represent a benefit to healthcare. The other, written by an Oxford research fellow, makes the case that while gene editing is not without controversy it should be developed.
The first author makes the point that social inequality would increase between those who were and were not genetically modified. While the second author makes the distinction that gene editing embryos is about modifying life where it already existed versus artificial selection which chooses which embryo is allowed to continue developing.